Small Molecules

SB431542

Activin/BMP/TGFβ pathway inhibitor;
Inhibits ALK4, ALK5, and ALK7

Catalog #	72232	1 mg
	72234	10 mg

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

SB431542 is a selective and potent inhibitor of the transforming growth factor (TGF)-β, Activin, and Nodal pathways. It inhibits the TGF-β type I receptors ALK 5 (IC_{50} = 94 nM), ALK4 (IC_{50} = 140 nM), and ALK7 by competing for the ATP binding site. It does not inhibit the BMP type I receptors ALK2, ALK3, and ALK6 (Inman et al.; Laping et al.).

Molecular Name:	SB431542
Alternative Names:	SB-431542
CAS Number:	301836-41-9
Chemical Formula:	$C_{22}H_{16}N_4O_3$
Molecular Weight:	384.4 g/mol
Purity:	≥ 98%
Chemical Name:	4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide
Structure:	

Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com.
Solubility:	· Absolute ethanol ≤ 5.2 mM · DMSO ≤ 50 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 1 mg in 260 µL of DMSO. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

REPROGRAMMING
· Replaces SOX2 in the reprogramming of mouse fibroblasts to induced pluripotent stem (iPS) cells (Ichida et al.).
· Increases the efficiency of reprogramming human somatic cells to iPS cells, in combination with PD0325901 (Catalog #72182) and Thiazovivin (Catalog #72252; Lin et al.).
· Direct lineage reprogramming of fibroblasts to mature neurons, in combination with CHIR99021 (Catalog #72052), ISX-9 (Catalog #73202), Forskolin (Catalog #72112), and I-BET151 (Catalog #73712; Li et al.).
DIFFERENTIATION
· Promotes differentiation of neural progenitor cells from human pluripotent stem cells (PSCs), in combination with either LDN193189 (Catalog #72146) or Noggin (Catalog #78060; Chambers et al. 2009; Chambers et al. 2012).
· Promotes proliferation and sheet formation of mouse embryonic stem (ES)-derived endothelial cells (Watabe et al.).
· Enhances differentiation of cardiomyocytes from mouse and human PSCs (Kattman et al.).
· Inhibits the self-renewal and causes differentiation of human PSCs, demonstrating the importance of the TGFβ/Activin/Nodal pathway in their maintenance (James et al.; Vallier et al.).

References

Chambers SM et al. (2012) Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol 30(7): 715–20.
Chambers SM et al. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27(3): 275–80.
Ichida JK et al. (2009) A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5(5): 491–503.
Inman GJ et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62(1): 65–74.
James D et al. (2005) TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132(6): 1273–82.
Kattman SJ et al. (2011) Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8(2): 228–40.
Laping NJ et al. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62(1): 58–64.
Li X et al. (2015) Small-molecule-driven direct reprogramming of mouse fibroblasts into functional neurons. Cell Stem Cell 17(2): 195–203.
Lin T et al. (2009) A chemical platform for improved induction of human iPSCs. Nat Methods 6(11): 805–8.
Vallier L et al. (2005) Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 118(Pt 19): 4495–509.
Watabe T et al. (2003) TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 163(6): 1303–11.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, please visit our website at www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.